ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release first quarter ...

The coupon rate for the NCD has been fixed between 11 per cent to 12.50 per cent for tenures of 13, 24, 36, 60 and 68 months.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Evogene's stock surged on news of ICL's acquisition of Lavie Bio's operations, strengthening ICL's position in ag-biologicals ...

ICL Fincorp Ltd has announced the launch of its fifth public issue of secured, redeemable Non-Convertible Debentures (NCDs), ...

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a ...

ICL Group shows strong upside with bullish charts, solid cash flow, and improving fundamentals. Find out why ICL is a buy.

ICL Fincorp plans to raise Rs 100 crore through a public issue of NCDs for business growth. The NCD will open on April 25, ...

ICL plans to acquire ag-biochemical tech firm Lavie Bio from Evogene Ltd. Lavie Bio is a recognized leader in the ag-biologicals industry with a robust pipeline of microbiome-based products.

Key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, the company's microbial bank and data assets, the majority of the company's development programs ...

Evogene (EVGN) signed a definitive agreement under which ICL will acquire the majority of activity of Evogene’s subsidiary, Lavie Bio. As part ...

This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for ...